Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

Obamacare winners and losers

NPR looks at what the federal government can learn from Massachusetts as health insurance exchanges roll out. Other media outlets check in with insurers, Wall Street traders, health care stakeholders and those who had previously been denied coverage in the individual insurance market.

2 Oct 2013

First Edition: October 1, 2013

Today's headlines detail how the federal government has been shutdown as a result of the ongoing congressional battle over the health law. Still, even as House and Senate lawmakers were unable to overcome this issue to reach a deal to provide funding to continue government operations, Oct. 1 is still the official launch of the overhaul's online insurance marketplaces.

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Marriage improves outcomes among patients with cancer, says oncologist

New results from a large retrospective study of the National Cancer Institute's SEER database show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients.

24 Sep 2013

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Halozyme Therapeutics, Inc. announced today that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer.

2 Sep 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

A groundbreaking peer reviewed case report by Dr. Isaac Eliaz, M.D. of Amitabha Medical Clinic, demonstrates for the first time the clinical use of novel biomarker galectin-3 to assess cancer progression and inflammation.

19 Aug 2013

Study: Immune-regulating molecules can trigger lymphomas

A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

9 Aug 2013

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

Eisai Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process.

9 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma-a key factor in tailoring patient management plans-has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine.

2 Aug 2013

Study offers new hope for treatment of diffuse large B-cell lymphoma

Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.

2 Aug 2013

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study has found.

1 Aug 2013

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer.

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

Non Hodgkin's Lymphoma News and Research

Further Reading

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Phase 3 study of idelalisibin reports positive results in CLL patients

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Obamacare winners and losers

First Edition: October 1, 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Marriage improves outcomes among patients with cancer, says oncologist

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

Study: Immune-regulating molecules can trigger lymphomas

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

ImmunoGen reports net loss of $21.9 million in Q4 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

Study offers new hope for treatment of diffuse large B-cell lymphoma

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

Technique for developing more targeted drugs using molecular "robots"

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News